Mohammed O Suraju
Overview
Explore the profile of Mohammed O Suraju including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suraju M, Gordon D, Kahl A, McCracken A, Maduokolam E, Grimmett J, et al.
J Surg Oncol
. 2024 Oct;
PMID: 39364893
Background: Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy of the liver and has the worst prognosis of any tumor arising from the liver, with a 5-year survival as...
2.
Suraju M, Kahl A, Nayyar A, Turaczyk-Kolodziej D, McCracken A, Gordon D, et al.
J Gastrointest Surg
. 2024 Sep;
28(12):1994-2000.
PMID: 39293732
Background: Although advancements in surgical planning and multidisciplinary care have improved the survival of patients with hepatopancreatic cancers in recent years, the impact of the rurality of patient residence on...
3.
Chang J, Suraju M, Tran C, Chan C, Ear P, Howe J, et al.
J Surg Res
. 2024 Jul;
302:53-63.
PMID: 39083906
Introduction: Studies conflict on whether sex influences survival in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). GEP-NETs express receptors and genes responsive to female hormones. We hypothesized that women would have improved survival...
4.
Ahmad S, Ganguli S, Suraju M, Freischlag K, Jehan F, Pancholia S, et al.
J Gastrointest Surg
. 2024 Jun;
28(9):1443-1449.
PMID: 38878958
Background: There has been an increase in the elderly patient population seeking care for pancreatic ductal adenocarcinoma (PDAC). This study aimed to delineate the effectiveness of therapeutic options in nonagenarians...
5.
Goffredo P, Suraju M, Mott S, Troester A, Weaver L, Mishra A, et al.
Ann Surg Oncol
. 2024 May;
31(10):6432-6442.
PMID: 38814551
Background: Pathologic complete response (pCR) after preoperative chemoradiation (nCRT) correlates with improved overall survival for patients with locally advanced rectal cancers (LARCs). Escalation protocols including total neoadjuvant therapy (TNT), which...
6.
Suraju M, Freischlag K, McKeen A, Nayyar A, Thompson D, Gordon D, et al.
J Surg Oncol
. 2024 Apr;
129(8):1449-1455.
PMID: 38685721
Background: Although correlation between center volume and survival has been reported for several complex cancers, it remains unknown if this is true for colorectal neuroendocrine carcinomas (CRNECs). We hypothesized that...
7.
Kakish H, Suraju M, Seth A, DiGioia O, Pawar O, Kwon Y, et al.
J Gastrointest Surg
. 2024 Apr;
28(7):1062-1066.
PMID: 38653337
Background: The optimal surgical option in patients with multifocal hepatocellular carcinoma (MHCC) is an area of active research. The preference varies based on geographic variations and institutional policies. We sought...
8.
Thompson D, Breyfogle E, Tran C, Suraju M, Mishra A, Lanewalla H, et al.
Surg Open Sci
. 2024 Apr;
19:95-100.
PMID: 38601734
Background: Frailty has been associated with worse postoperative outcomes. The 5-factor modified frailty index (mFI-5) is an objective measure although its validity in measuring frailty in patients undergoing ileal pouch-anal...
9.
Kakish H, Suraju M, Davis E, Seth A, Kwon Y, Aziz H
J Surg Oncol
. 2024 Feb;
129(6):1113-1120.
PMID: 38333997
Introduction: The management of T2 multifocal hepatocellular carcinoma (MHCC) is controversial, and the comparative impact of liver resection (LR) versus tumor ablation (TA) on survival continues to be debated. The...
10.
Suraju M, Freischlag K, Jacob D, Thompson D, McKeen A, Tran C, et al.
Surgery
. 2023 Oct;
175(3):735-742.
PMID: 37867105
Background: Mixed neuroendocrine-non-neuroendocrine neoplasms are a rare subtype of neuroendocrine neoplasm consisting of ≥30% each of neuroendocrine and non-neuroendocrine differentiation. Neuroendocrine carcinomas are poorly differentiated neuroendocrine tumors. The epidemiology and...